Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib
Publication
, Conference
Ritchie, EK; Catchatourian, R; Klisovic, RB; Pinilla-Ibarz, J; Deininger, MW; Erba, HP; Radich, JP; Savona, MR; Dautaj, I; Purkayastha, D ...
Published in: BLOOD
December 7, 2017
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 7, 2017
Volume
130
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
59th Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ritchie, E. K., Catchatourian, R., Klisovic, R. B., Pinilla-Ibarz, J., Deininger, M. W., Erba, H. P., … Mauro, M. J. (2017). Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. In BLOOD (Vol. 130). Atlanta, GA: AMER SOC HEMATOLOGY.
Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, Javier Pinilla-Ibarz, Michael W. Deininger, Harry P. Erba, Jerald P. Radich, et al. “Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.” In BLOOD, Vol. 130. AMER SOC HEMATOLOGY, 2017.
Ritchie EK, Catchatourian R, Klisovic RB, Pinilla-Ibarz J, Deininger MW, Erba HP, et al. Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. In: BLOOD. AMER SOC HEMATOLOGY; 2017.
Ritchie, Ellen K., et al. “Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.” BLOOD, vol. 130, AMER SOC HEMATOLOGY, 2017.
Ritchie EK, Catchatourian R, Klisovic RB, Pinilla-Ibarz J, Deininger MW, Erba HP, Radich JP, Savona MR, Dautaj I, Purkayastha D, Habucky K, Mauro MJ. Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. BLOOD. AMER SOC HEMATOLOGY; 2017.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 7, 2017
Volume
130
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
59th Annual Meeting of the American-Society-of-Hematology (ASH)
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology